CatSci, a fast growing, adaptable and award-winning process research and development contract research organisation (CRO), is furthering its global growth strategy to support innovator pharma in meeting their Chemistry, Manufacturing and Controls (CMC) demands.
As part of this approach, CatSci has hired a Head of Business Development for North America and has completed the prestigious Goldman Sachs 10,000 Small Businesses programme.
CatSci has hired Dr Jas Douville as the Head of Business Development for North America. Jas is permanently based in this region to focus on further establishing long-term relationships with prospective and current customers. The overall aim of this newly created role is to help customers to deliver affordable, best-in-class small molecule therapeutics to meet the evolving healthcare needs of the world.
Jas brings a wealth of diverse expertise to the role, with an extensive background in both business development and drug discovery. He completed a PhD in Organic Chemistry from the Université de Sherbrooke, before working in R&D, direct sales and business development for the global chemistry and pharma industries. This new appointment is critical in supporting CatSci’s mission to become the preferred partner to innovator pharma for the development of economically and environmentally sustainable chemical processes for small molecules.
In order to further grow CatSci’s global customer base, Dr Ross Burn, Chief Executive Officer, recently completed the highly esteemed 10,000 Small Businesses programme funded by Goldman Sachs. The programme is run in partnership with the Said Business School at Oxford University, the Aston Centre for Growth at Aston University, Leeds University Business School, and Manchester Metropolitan University Business School. The course accelerates the business growth of organisations, helping entrepreneurs to create jobs and economic opportunities. This course has enabled CatSci to expedite its expansion process, with the organisation now aiming to create 25 jobs as part of a two-year business plan.
Dr Ross Burn, Chief Executive Officer, said: “We are delighted that CatSci is going from strength to strength in its strategic expansion plan. It is fantastic to have Jas on board as we apply the knowledge gained through the 10,000 Small Business Programme to increase our international presence in North America and beyond.”
Dr Jas Douville, Head of Business Development for North America, said: “By becoming a member of the CatSci team, I am joining a group of highly skilled, dedicated and like-minded people that aim to understand and solve difficult chemistry challenges. Our common goal is allowing our customers to accelerate the development path from the lab through the clinic and all the way to commercial production for novel small molecule therapeutics.”